Teleflex has announced the results of several research studies that further support the safety and efficacy of the UroLift system for men living with enlarged prostate, benign prostatic hyperplasia (BPH), or those who have a wide range of prostate sizes and/or a median lobe obstruction. The data were presented at the 37th Annual European Association of Urology (EAU) Congress in Amsterdam (1—4 July) and virtually.
Key findings include:
- Pooled outcomes of over 300 controlled subjects from five clinical studies revealed most men shifted to lower international prostate symptom score (IPSS) symptom severity after treatment with prostatic urethral lift (PUL). The majority of subjects (79%) improved by three points or more, and 66% of those patients moved into a lower IPSS severity grade 12 months post-treatment.
- Comparative evaluation of real-world and controlled trial outcomes of PUL demonstrated that symptom improvement is not correlated with prostate size and shape. The study examined PUL outcomes in differing gland sizes and morphologies, comparing controlled trial results from BPH6 for patients with small prostate sizes and MedLift for patients with obstructive median lobes. At 24 months, all groups demonstrated significant and sustained IPSS improvement.
- An analysis of US healthcare claims revealed higher de novo prescription rates after transurethral resection of the prostate (TURP) and photoselective vaporisation of the prostate (PVP) compared to PUL. The study revealed that post-surgical medication usage was significantly higher for BPH patients who were treated with more invasive surgical procedures as compared to those treated with the UroLift system.
“The UroLift system is the most well studied minimally invasive surgical therapy for BPH. In a combined analysis from five controlled studies, we found that the majority of men who had received the procedure demonstrated measurable improvement in their BPH symptoms, flow rate, and quality of life. Subjects [also] preserved their sexual function,” said Claus G Roehrborn, urologist at the University of Texas Southwestern Medical Center (Dallas, USA) and a lead author on the paper.
“The evidence presented at EAU means that urologists can further help their BPH patients make an objective, data-driven, and informed decision based on real-world evidence, particularly when faced with prostate sizes and shapes that fall outside of the range of randomised clinical trials. Our research showed not only rapid, but also durable improvement,” said Christian Gratzke, medical director, urology clinic, University Hospital, Freiburg (Freiburg, Germany).
